Sartorius Stedim Biotech: Dynamic First Quarter in 2015 | Forecast Revised Upwards

Regulatory News:

Sartorius Stedim Biotech (Paris:DIM), a leading supplier for the biopharmaceutical industry, today pre-announced results for the first quarter 2015. Based on preliminary figures sales revenue grew around 22% in constant currencies to approximately €204 million (reported gain: around 33%).

Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year.

Based on the results of the first three months, Sartorius Stedim Biotech has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase approximately 7% to 10% (previous guidance: approx. 4% to 7%). Management projects that the company‘s underlying EBITDA margin in constant currencies will reach around 24.5% to 25% (previous guidance: around 24.0% to 24.5%).

Further information will be published on April 20, 2015.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.